{"id":"W4415942864","doi":"10.1016/j.annonc.2025.08.1760","title":"1124P Lenvatinib + pembrolizumab (L + P) in participants (Pts) with advanced or recurrent endometrial cancer (aEC): Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Lenvatinib; Chemotherapy; Endometrial cancer; Phases of clinical research; Subgroup analysis; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008877884,0.0003774294,0.0006278289,0.0001750625,0.0002167535,0.0004520083,0.0003285821,0.000524128,0.004109865],"category_scores_gemma":[0.001328252,0.0002508005,0.001568791,0.000360208,0.0001548038,0.0005535007,0.0004327653,0.001322615,0.0004397966],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004470814,"about_ca_system_score_gemma":0.0008980044,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003137792,"about_ca_topic_score_gemma":0.006392087,"domain_scores_codex":[0.9995983,0.0001656509,0.00003417367,0.00008512314,0.00003840278,0.00007836393],"domain_scores_gemma":[0.9995994,0.0000770782,0.0001564266,0.00002492115,0.00003713478,0.0001050001],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6260694,0.004878447,0.2420742,0.004247992,0.0124881,0.0001832551,0.0002243835,0.0006674615,0.002915914,0.0005618649,0.009196188,0.09649276],"study_design_scores_gemma":[0.1302748,0.1197627,0.7064372,0.001313129,0.02228508,0.000305983,0.0005755583,0.001118078,0.001541979,0.001077698,0.01523631,0.0000715344],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831806,0.006555229,0.0002250031,0.000448085,0.0001893616,0.0004164837,0.005588967,0.00002040114,0.00337588],"genre_scores_gemma":[0.9928739,0.001816946,0.0002611574,0.0003232826,0.00009690325,0.0004542676,0.002248842,0.000004595794,0.001920013],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004109865,"threshold_uncertainty_score":0.01374882,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1415611076472271,"score_gpt":0.4622116491794812,"score_spread":0.3206505415322541,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}